QID 753039

Date Published: 2022-12-22

QID 753039: SUSE Enterprise Linux Security Update for the Linux Kernel (SUSE-SU-2022:4574-1)

SUSE has released a security update for kernel to fix the vulnerabilities.

Affected product(s):
SUSE Linux Enterprise Server 15 SP1|SUSE Linux Enterprise Server for SAP Applications 15 SP1
SUSE Linux Enterprise Server for SAP Applications 15 SP1

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as Critical - 10 severity.
  • CVSS V2 rated as Medium - 5.4 severity.
    • Solution
    Refer to SUSE security advisory SUSE-SU-2022:4574-1 for updates and patch information.
    Vendor References

    CVEs related to QID 753039

    CVE-2022-3542 | CVE-2022-41850 | CVE-2022-3646 | CVE-2022-42329 | CVE-2022-3643 | CVE-2022-28693 | CVE-2022-3629 | CVE-2022-3635 | CVE-2022-2964 | CVE-2022-3621 | CVE-2022-4095 | CVE-2021-4037 | CVE-2022-4378 | CVE-2022-42896 | CVE-2022-41858 | CVE-2022-43750 | CVE-2022-40307 | CVE-2022-3521 | CVE-2022-3565 | CVE-2022-42328 | CVE-2022-42703 | CVE-2022-42895 | CVE-2022-45934 | CVE-2022-43945 | CVE-2022-3567 | CVE-2022-3545 | CVE-2022-3649 | CVE-2022-3903 | CVE-2022-3628 | CVE-2022-2153 | CVE-2022-3424 | CVE-2022-3524 | CVE-2022-3594 | CVE-2022-40768 | CVE-2022-3169 | CVE-2022-3586 |
    Software Advisories
    Advisory ID Software Component Link
    SUSE-SU-2022:4574-1 SUSE Enterprise Linux URL Logo lists.suse.com/pipermail/sle-security-updates/2022-December/013279.html
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].